[go: up one dir, main page]

MX2019005600A - Molecula que induce la degradacion de la proteina ras y composiciones farmaceuticas. - Google Patents

Molecula que induce la degradacion de la proteina ras y composiciones farmaceuticas.

Info

Publication number
MX2019005600A
MX2019005600A MX2019005600A MX2019005600A MX2019005600A MX 2019005600 A MX2019005600 A MX 2019005600A MX 2019005600 A MX2019005600 A MX 2019005600A MX 2019005600 A MX2019005600 A MX 2019005600A MX 2019005600 A MX2019005600 A MX 2019005600A
Authority
MX
Mexico
Prior art keywords
ras protein
protein degradation
pharmaceutical composition
inducing molecule
degradation inducing
Prior art date
Application number
MX2019005600A
Other languages
English (en)
Inventor
Miyamoto Etsuko
Ozawa Masaaki
Original Assignee
Univ Tokyo Science Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo Science Found filed Critical Univ Tokyo Science Found
Publication of MX2019005600A publication Critical patent/MX2019005600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una molecula que induce la degradacion de la proteina Ras que puede inducir la degradacion de las proteinas Ras y una composicion farmaceutica que contiene esta molecula que induce la degradacion de la proteina Ras; la molecula que induce la degradacion de la proteina Ras es un conjugado de una molecula de afinidad de la proteina Ras que tiene afinidad por las proteinas Ras, y una etiqueta que induce la proteolisis que tiene afinidad por la proteasa y no inhibe la proteolisis de las proteinas por la proteasa.
MX2019005600A 2016-11-15 2017-11-13 Molecula que induce la degradacion de la proteina ras y composiciones farmaceuticas. MX2019005600A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016222683 2016-11-15
PCT/JP2017/040779 WO2018092723A1 (ja) 2016-11-15 2017-11-13 Ｒａｓタンパク質分解誘導分子及び医薬組成物

Publications (1)

Publication Number Publication Date
MX2019005600A true MX2019005600A (es) 2019-10-09

Family

ID=62146510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005600A MX2019005600A (es) 2016-11-15 2017-11-13 Molecula que induce la degradacion de la proteina ras y composiciones farmaceuticas.

Country Status (15)

Country Link
US (1) US11052154B2 (es)
EP (1) EP3542824A4 (es)
JP (1) JP7061800B2 (es)
KR (1) KR20190087460A (es)
CN (1) CN110035775A (es)
AU (1) AU2017361155B2 (es)
BR (1) BR112019009645A2 (es)
CA (1) CA3043805A1 (es)
IL (1) IL266632B (es)
MX (1) MX2019005600A (es)
MY (1) MY195945A (es)
PH (1) PH12019501064A1 (es)
TW (1) TWI811197B (es)
WO (1) WO2018092723A1 (es)
ZA (1) ZA201903657B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3807272A1 (en) 2018-06-13 2021-04-21 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2021222138A1 (en) * 2020-04-27 2021-11-04 Development Center For Biotechnology Compounds for mutant ras protein degradation
EP4089102A1 (en) * 2021-05-14 2022-11-16 Insusense ApS Modulators of sortilin activity
CN115969980B (zh) * 2022-12-30 2023-10-24 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗胃癌的药物中的应用
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
AU2864100A (en) 1999-02-01 2000-08-18 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
JP2008533986A (ja) 2005-03-25 2008-08-28 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド 変異型ｐ５３の共通エピトープに対するヒト合成単鎖抗体およびその使用
JP2009149524A (ja) 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
WO2008147536A1 (en) 2007-05-24 2008-12-04 President And Fellows For Harvard College Methods and compositions for enhancing proteasome activity
WO2010125620A1 (ja) 2009-04-30 2010-11-04 国立大学法人大阪大学 哺乳類細胞におけるタンパク質分解誘導方法
EP2588129A4 (en) * 2010-06-30 2014-07-09 Univ Brandeis ON SMALL MOLECULES TARGETED PROTEIN REMOVAL
JP5934986B2 (ja) 2011-09-07 2016-06-15 公益財団法人ヒューマンサイエンス振興財団 アポトーシス阻害タンパク質リガンド−エストロゲン受容体リガンドハイブリッド化合物並びにそれを利用したエストロゲン受容体分解誘導剤及び乳癌、子宮頚癌又は卵巣癌の予防及び治療剤
US8652656B2 (en) 2011-11-14 2014-02-18 Universal Display Corporation Triphenylene silane hosts
MX394449B (es) 2012-01-12 2025-03-11 Univ Yale Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
JP2013177444A (ja) 2013-05-18 2013-09-09 Isao Kajisa ヒトｉＰＳのＴ細胞再分化テロメア若返り炎症老化止めｐ５３とＲｂ分解経口不老不死薬５
US10017540B2 (en) * 2015-03-11 2018-07-10 California Institute Of Technology Cyclic peptide binder against oncogenic K-Ras
EP3868878B1 (en) 2015-06-19 2024-08-28 Tokyo University of Science Foundation Protein degradation inducing tag and usage thereof
CN110062632A (zh) * 2016-11-15 2019-07-26 学校法人东京理科大学 p53分解诱导分子和药物组合物
US20190369111A1 (en) * 2016-11-15 2019-12-05 Tokyo University Of Science Foundation Molecular kinetics evaluation method and screening method

Also Published As

Publication number Publication date
US11052154B2 (en) 2021-07-06
ZA201903657B (en) 2020-12-23
BR112019009645A2 (pt) 2019-09-17
EP3542824A1 (en) 2019-09-25
IL266632A (en) 2019-07-31
IL266632B (en) 2022-03-01
JPWO2018092723A1 (ja) 2019-10-17
TWI811197B (zh) 2023-08-11
WO2018092723A1 (ja) 2018-05-24
JP7061800B2 (ja) 2022-05-02
KR20190087460A (ko) 2019-07-24
MY195945A (en) 2023-02-27
CA3043805A1 (en) 2018-05-24
AU2017361155A1 (en) 2019-06-06
EP3542824A4 (en) 2020-11-04
TW201825677A (zh) 2018-07-16
CN110035775A (zh) 2019-07-19
US20200000927A1 (en) 2020-01-02
PH12019501064A1 (en) 2019-08-19
AU2017361155B2 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
HUE054568T2 (hu) Továbbfejlesztett kettõs specificitású polipeptid molekula
ECSP18082207A (es) Neoantígenos y métodos de su uso
MX2017006866A (es) Pares de unión para producción de péptidos.
SG10201909716RA (en) Modified j-chain
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
MX392945B (es) Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.
WO2015179635A3 (en) Ras inhibitory peptides and uses thereof
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
MX2019014504A (es) Inmunoglobulinas de union a agrecano.
MX2019007152A (es) Peptido novedoso.
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica
EA201791716A1 (ru) Фармацевтический состав
EA201792262A1 (ru) Пироглутамат вортиоксетина
MX2020006510A (es) Peptido novedoso.
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
MX394409B (es) Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
NZ744289A (en) Composition containing amino acids
MX393805B (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
EA201892085A1 (ru) Новые белки, полученные из альфа-1-микроглобулина, и их применение
MX2021001361A (es) Composicion liquida de fibrinogeno humano.